Research programme: arrhythmias therapeutics - Pierre FabreAlternative Names: 16915; F 16915
Latest Information Update: 16 Jul 2016
At a glance
- Originator Pierre Fabre
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Arrhythmias
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Arrhythmias in France
- 31 Dec 2007 Preclinical trials in Arrhythmias in France (unspecified route)